help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on April 1, 2004, doi:10.1165/rcmb.2003-0307OC
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-0307OCv1
31/2/162    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, S.-M.
Right arrow Articles by Martin, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, S.-M.
Right arrow Articles by Martin, T. R.
American Journal of Respiratory Cell and Molecular Biology. Vol. 31, pp. 162-170, 2004
© 2004 American Thoracic Society
DOI: 10.1165/rcmb.2003-0307OC

Differential Regulation of Membrane CD14 Expression and Endotoxin-Tolerance in Alveolar Macrophages

Shu-Min Lin, Charles W. Frevert, Osamu Kajikawa, Mark M. Wurfel, Kimberly Ballman, Stephen Mongovin, Venus A. Wong, Amy Selk and Thomas R. Martin

Pulmonary Research Laboratories at the VA Puget Sound Medical Center, and the Division of Pulmonary/Critical Care Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, Washington; and Department of Thoracic Medicine II, Chang Gung Memorial Hospital, Taipei, Taiwan

Address correspondence to: Charles W. Frevert, D.V.M., Sc.D., Pulmonary Research Group, VA Puget Sound Medical Center, 1660 S. Columbian Way, 151L, Seattle, WA 98108. E-mail: cfrevert{at}u.washington.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
CD14 is important in the clearance of bacterial pathogens from lungs. However, the mechanisms that regulate the expression of membrane CD14 (mCD14) on alveolar macrophages (AM) have not been studied in detail. This study examines the regulation of mCD14 on AM exposed to Escherichia coli in vivo and in vitro, and explores the consequences of changes in mCD14 expression. The expression of mCD14 was decreased on AM exposed to E. coli in vivo and AM incubated with lipopolysaccharide (LPS) or E. coli in vitro. Polymyxin B abolished LPS effects, but only partially blocked the effects of E. coli. Blockade of extracellular signal–regulated kinase pathways attenuated LPS and E. coli–induced decrease in mCD14 expression. Inhibition of proteases abrogated the LPS-induced decrease in mCD14 expression on AM and the release of sCD14 into the supernatants, but did not affect the response to E. coli. The production of tumor necrosis factor-{alpha} in response to a second challenge with Staphylococcus aureus or zymosan was decreased in AM after incubation with E. coli but not LPS. These studies show that distinct mechanisms regulate the expression of mCD14 and the induction of endotoxin tolerance in AM, and suggest that AM function is impaired at sites of bacterial infection.

Abbreviations: alveolar macrophages, AM • differential interference contrast, DIC • dimethyl sulfoxide, DMSO • extracellular signal–regulated kinase, ERK • interleukin, IL • lipopolysaccharide, LPS • membrane CD14, mCD14 • mitogen-activated protein, MAP • phosphate-buffered saline, PBS • phosphatidylinositol-specific phospholipase, PI-PLC • soluble CD14, sCD14 • sodium dodecyl sulfate–polyacrylamide gel electrophoresis, SDS-PAGE • tumor necrosis factor-{alpha}, TNF-{alpha}


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Gram-negative pneumonia is an important cause of morbidity and mortality in medical patients (1, 2). The innate immune system is responsible for the clearance of bacteria from the lungs, and an effective response results in the clearance of bacterial pathogens with minimal tissue injury. In contrast, an ineffective innate immune response results in bacterial proliferation, increased lung injury, and the development of sepsis and septic shock (3, 4).

Lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria, provides a potent signal to the innate immune system and is often used to model gram-negative infections in vitro and in vivo. However, studies show that whole Escherichia coli causes a more potent and prolonged activation of the innate immune system when compared with equivalent amounts of E. coli LPS (5). Therefore, the activation and subsequent responses of the innate immune system to LPS and whole E. coli may differ.

CD14, the receptor for LPS, is implicated in various immune responses including activation of the innate immune system (6), bacterial phagocytosis (7), and clearance of apoptotic cells (8). Macrophages recognize LPS via membrane CD14 (mCD14) and Toll-like receptor-4 (TLR4), a member of the Toll-like receptor family which mediate signaling in response to a number of microbial components (9–11). Recognition of LPS by the CD14/TLR4/MD-2 complex activates intracellular signaling pathways involving mitogen-activated protein (MAP) kinases, resulting in the production of proinflammatory cytokines and chemokines (12–14). In rabbits with E. coli pneumonia, blockade of CD14 protected against the deleterious systemic response that occurs in sepsis; however, CD14 blockade resulted in an increased bacterial burden in the lungs (15). This suggests that the CD14 pathway is important in local intrapulmonary host defenses and the clearance of gram-negative bacteria from lungs. However, little is known about the mechanisms that regulate the expression of mCD14 on alveolar macrophages (AM) at sites of bacterial infections.

Pre-administration of LPS in vitro or in vivo is known to downregulate responses to a second LPS challenge (reviewed in Refs. 16 and 17). This phenomenon, known as endotoxin tolerance, results in animals, humans, and cells becoming refractory to a second challenge of LPS after the initial exposure. Initially, it was thought that tolerance was beneficial due to its ability to diminish the inflammatory response to LPS. However, the development of tolerance in patients with sepsis may worsen clinical outcomes due to the development of immune dysregulation (17–19). A potential mechanism whereby endotoxin-tolerance develops is the downregulation of LPS receptors such as mCD14 on macrophages (16, 20).

The objectives of this study were twofold. First the expression of mCD14 on AM was measured in vivo at sites of bacterial infection and in vitro to define the mechanisms responsible for changes in mCD14 expression. The second objective was to determine whether decreased expression of mCD14 after incubation with LPS or whole E. coli affects the response of AM to a subsequent challenge with E. coli, Staphylococcus aureus, or zymosan. The data show that LPS and whole E. coli regulate the cell surface expression of CD14 and the development of tolerance by distinct mechanisms, and suggest that AM function may be downregulated at sites of bacterial infection in the lungs.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Reagents and Antibodies
LPS from E. coli serotype 0111:B4 was purchased from List Biological Laboratories (Campell, CA). E. coli serotype K-1 was a clinical isolate obtained from a patient with bacteremia due to biliary sepsis (15). The inhibitor of phosphatidylinositol-specific phospholipase ET-18-OCH3, and kinase inhibitors SB203580 (p38 inhibitor), PD98059 (extracellular signal–regulated kinase [ERK] inhibitor), and SP600125 (JNK inhibitor) were purchased from Calbiochem Co. (La Jolla, CA). The protease inhibitor cocktail (P1860) and polymyxin B were obtained from Sigma-Aldrich Co. (St. Louis, MO). The Vector "Elite" ABC-HP kit was from Vector Laboratories (Burlingame, CA). S. aureus–BODIPY and Zymosan-BODOPY bioparticles were purchased from Molecular Probes (Eugene, OR). The antibodies to ERK and phosphorylated ERK were from Cell Signaling (Beverly, MA). The polyclonal goat anti-rabbit CD14, soluble CD14, polyclonal goat anti-rabbit tumor necrosis factor (TNF)-{alpha}, and recombinant rabbit TNF-{alpha} were generous gifts of John Mathison (Scripps Research Institute, La Jolla, CA). The limulus amebocyte lysate kit was from Biowhittaker Co. (Walkersville, MD). Complete RPMI was made up of RPMI 1640 (Biowhittaker, Walkersville, MD) supplemented with 10% fetal calf serum (Hyclone, Logan, UT), 10 mM HEPES (Gibco, Grand Island, NY), 2 mM L-glutamine (Gibco), 50 U/ml penicillin, and 50 µg/ml streptomycin (Penn/Strep; Gibco).

Rabbit Model of Bacterial Pneumonia
The Animal Research Committee of the Veterans Affairs Puget Sound Health Care System approved all of the experiments. Female New Zealand White rabbits, specific pathogen–free, weighing 3.0–3.5 kg were purchased from Western Oregon Rabbit Co. (Philomath, OR) and housed in the animal facility until the day of the experiment.

Induction of gram-negative bacterial pneumonia. Rabbits were anesthetized with a combination of intravenous ketamine (10 mg/kg) and xylazine (3 mg/kg) and allowed to breathe spontaneously. To induce pneumonia, anesthetized rabbits were placed prone on a 20-degree incline with the head elevated. Then 1.0 ml of the E. coli suspension (1 x 107 or 1 x 109 cfu/ml) was instilled in the right and left lower lobe bronchus using PE90 tubing (Intramedic, Sparks, MD) advanced through the biopsy channel of a pediatric bronchoscope (Pentax, Tokyo, Japan). Bacteria were mixed with 1% colloidal carbon (Pelikan, Hanover, Germany) to aid in identifying the instilled areas at necropsy. The rabbits were placed on a heated water blanket (Gaymar Industries, Orchard Park, NY) after the instillation to maintain body temperature following anesthesia.

Immunohistochemistry
To prepare tissue for immunohistochemistry, paraffin-embedded lung tissue was sectioned into 4- to 6-µm slices and water-mounted onto charged Superfrost Plus glass slides (Fisher Scientific, Pittsburgh, PA). Slides were deparaffinized by washing twice in xylene for 5 min and rehydrated by washing twice in 100% ethanol for 3 min, twice in 95% ethanol for 3 min, and once in dH2O for 5 min. Endogenous peroxidases were blocked by incubating slides with 0.3% H2O2 in methanol for 60 min, and then rinsed twice with PBS. The slides were rinsed twice with phosphate-buffered saline (PBS) for 5 min and the samples digested for 10 min in 0.05% Pronase. After digestion, the slides were rinsed twice with PBS for 5 min and blocked in PBS containing 5% normal rabbit serum (Vector, Burlingame, CA) and 5% nonfat milk protein for 60 min at room temperature.

Next, CD14 and rabbit AM were visualized in lung tissue sections by immunohistochemistry using 5 µg/ml of polyclonal goat anti-rabbit CD14 antibody and 5 µg/ml of mouse anti-rabbit AM antibody (DAKO, Carpenteria, CA). Primary antibodies were incubated with the tissue sections overnight in a moist chamber at 4°C. The slides were rinsed twice with PBS and labeled with an appropriate biotinylated secondary antibody for 2 h at 4°C. To detect the mouse anti-rabbit macrophage antibody, slides were incubated with biotinylated anti-mouse IgG, rinsed three times in PBS. The samples were labeled with streptavidin-horseradish peroxidase and incubated with tyramide–fluorescein isothiocyanate–(FITC). After rinsing twice in PBS, any avidin or biotin remaining in the tissues was blocked with the Avidin-Biotin Blocking Kit (Vector Laboratories). To detect rabbit CD14 in tissue, slides were incubated with biotinylated anti-goat IgG for 2 h and then incubated with streptavidin horseradish peroxidase for 30 min. The sections were rinsed, incubated with biotinyl-tyramide, rinsed again in PBS, and stained with streptavidin–Alexa 568 (Molecular Probes) at 1:200 and To-Pro-3 (Molecular Probes) at 1 µM. The slides were rinsed with PBS and then mounted with Vectashield hard mounting media (Vector Laboratories).

Imaging procedure for confocal microscopy. Visualization of positive immunostaining for CD14 and AM was performed with a Leica TCS-SP confocal microscope with an upright Leica DMR Microscope and Leica Confocal Software (Leica Microsystems, Heidelberg, Germany). Confocal microscopy was used to eliminate the fluorescent light from above and below the plane of focus. Differential interference contrast (DIC) was used to provide structural detail of the lungs. The lasers used were argon (488 nm) for detection of FITC, krypton (568 nm) for the detection of Alexa 568, and helium/neon (633 nm) for the detection of To-Pro-3. To calculate the optimum PMT setting for each laser line, the glow-over option of the Leica Confocal Software was used to maximize signal without over-saturating the image; and to minimize autofluorescence in the tissue. The pinhole for all images was set at 1 Airy Unit. For the negative controls, identical PMT and pinhole settings were used when capturing images.

Bronchoalveolar Lavage
The rabbit AM were obtained by bronchoalveolar lavage from healthy rabbits as described (15). The rabbits were anesthetized with a combination of ketamine (10 mg/kg) and xylazine (3 mg/kg) intravenously, then killed with pentobarbital and exsanguinated by cardiac puncture. The heart and lungs were removed en bloc, and the heart and surrounding soft tissue were carefully removed from lungs. The lungs were lavaged with five separate 30-ml aliquots of isotonic saline containing 0.6 mM EDTA at 37°C. The cells were spun at 200 x g to pellet cells, and were then washed twice with complete RPMI. The cell viability was determined by trypan blue exclusion, and in all cases the recovered cells were > 95% viable.

Culture of AM
AM were resuspended at 5 x 105 cells/ml in complete RPMI and placed in 6-well culture dishes in media, allowed to adhere for 60 min, and then washed three times with warm complete RPMI to remove nonadherent cells. The adherent cells were incubated for 24 h in complete RPMI, with PBS, 100 ng/ml LPS, or 1 x 106 cfu/ml of either live or heat-killed E. coli. To examine the roles of MAP kinases, rabbit AM were preincubated for 30 min with the vehicle control, dimethyl sulfoxide (DMSO), SB203580 (10 µM), PD98059 (30 µM), or SP600125 (25 µM), which are specific inhibitors of P38, ERK, and JNK kinases, respectively. The AM were next incubated in the presence of LPS or E. coli for an additional 24 h. In another set of experiments, the cells were incubated with polymyxin B (10 µg/ml), protease inhibitor cocktail (1:200 dilution), and ET-18-OCH3 (100 µM), which is an inhibitor of phosphatidylinositol-specific phospholipase (PI-PLC), for 30 min before adding LPS or E. coli. Preliminary studies were performed for each of the inhibitors to identify the maximal inhibitory concentration of each reagent on reversing the decreased mCD14 expression of E. coli–stimulated AM. The maximal inhibitory concentration for each inhibitor was identified as the concentration at which the dose–response curve reached a plateau and increasing amounts had no further effects on mCD14 expression in AM exposed to E. coli. The maximal inhibitory concentration was then used in all subsequent studies when AM were exposed to LPS or E. coli. Preliminary studies also showed that the concentration of each inhibitor used did not affect mCD14 expression on AM exposed to PBS for 24 h. After 24 h incubation, the supernatants were collected and saved at –70°C, and the adherent cells were resuspended and analyzed by flow cytometry.

Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis and Western Blotting
Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis–(PAGE) and Western Blotting were performed using a 4–15% polyacrylamide gradient gel (Bio-Rad, Hercules, CA) with Tris-glycine PAGE running buffer. Cell lysates (2 x 106 cells/100 µl) were loaded to the gel at 10 µl/well. The gel was then blotted onto nitrocellulose membrane (Hybond-ECL; Amersham Biosciences, Piscataway, NJ) using a Bjerrum and Schafer-Nielsen buffer (48 mM Tris, 39 mM glycine, 0.037% SDS, and 20% methanol, pH9.2). The transblotted membranes were incubated overnight with blocking buffer (I-Block; Tropix, Bedford, MA), then incubated with a rabbit anti-ERK, rabbit anti-phosphorylated ERK, or a goat anti-rabbit CD14 polyclonal antibody or a control goat antibody at 1 µg/ml at room temperature for 1 h. Finally the membranes were incubated with HRPO-labeled mouse anti-rabbit or rabbit anti-goat secondary antibody. Visualization of antibody–antigen complexes was visualized with chemiluminescence detecting reagents as described by the manufacturer (Super-Signal West Femto substrate; Pierce Biotechnology, Rockford, IL). Multiple films of the Western blot were obtained to ensure that the bands were not saturated.

Flow Cytometry
Rabbit AM were washed twice with PBS containing 0.1% sodium azide and 0.1% bovine serum albumin, then incubated with normal rabbit serum for 20 min on ice to block Fc receptors, and then incubated for 40 min with polyclonal goat anti-rabbit CD14 IgG, or control goat serum at 1:500 dilutions. After washing twice, cells were incubated for 30 min in buffer with 1:100 dilutions of PE-labeled donkey anti-goat antibodies specific to the primary antibodies. Cells were washed twice and examined by flow cytometry (FACScan; Becton Dickinson, San Jose, CA). At least 10,000 cell signals were obtained in each sample and the data were analyzed by WinMDI 2.8 software (Joseph Trotter, San Diego, CA).

Second Challenge of Rabbit AM with E. coli, S. aureus, or Zymogen
AM were incubated for 24 h in complete-RPMI with PBS, 100 ng/ml LPS, or 1 x 106 CFU/ml of live E. coli. The 24-h cell viability determined by trypan blue exclusion showed that there was no difference in viability between the treatment groups. The cells were washed twice with culture media and then incubated with PBS, BODIPY-labeled E. coli, S. aureus or zymosan for 2 or 4 h. The bacteria and zymosan were opsonized with heat-inactivated pooled rabbit serum and added to AM at a ratio of 10:1. After 2 h of incubation, the cells were spun at 200 x g and incubated with 0.1% trypan blue for 1 min to quench external fluorescence (7). The cells were washed with PBS containing 0.1% sodium azide and 0.1% bovine serum albumin and phagocytosis was measured by flow cytometry. Phagocytosis was measured as the percentage of cells containing fluorescent particles using the WinMDI 2.8 software. The supernatants of the 4-h incubation studies were saved at –70°C.

Concentrations of LPS, Soluble CD14, and TNF-{alpha}
The LPS concentrations in the supernatants of culture fluid were assessed using the quantitative chromogenic limulus amebocyte lysate assay (QCL 1000; Whittaker M.A. Bioproducts, Walkersville, MD) according to the manufacturer's instructions. The lower limit of LPS detection was 0.1 EU/ml. The concentrations of soluble CD14 (sCD14) and TNF-{alpha} in the culture supernatants were measured with rabbit-specific immunoassays (15, 21, 22). The assay sensitivities were sCD14 = 5 pg/ml and TNF-{alpha} = 10 pg/ml.

Statistics
Differences among groups were determined using one-way ANOVA and paired comparisons between groups were performed using Student's t test. Analysis of correlation between mCD14 and TNF{alpha} was performed using Pearson's coefficient of correlation. A P value of 0.05 was considered significant. Values are presented as means ± SEM.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Colocalization of CD14 and AM in Rabbit Lung Tissue
To determine whether the cell surface expression of CD14 changes in lungs of rabbits with E. coli pneumonia, immunohistochemistry was performed in paraffin-embedded lung sections from normal rabbits and rabbits E. coli pneumonia for 24 h. Immunohistochemistry performed with an enzymatic-based detection system and brightfield microscopy showed that in normal lungs CD14 was localized primarily to AM and ~ 100% of the AM stained positive. In contrast, there was considerable variability in the immunoreactivity of CD14 on AM from tissue sections obtained from infected rabbits with a consistent finding of decreased or absent immunoreactivity for CD14 on AM (data not shown).

To determine the cellular distribution of CD14 and to increase the sensitivity of antigen detection, immunohistochemistry was performed with Tyramide signal amplification (TSA) and confocal microscopy (23, 24). TSA amplification and confocal microscopy provided similar results to the previous studies and showed that in normal lungs, ~ 100% of normal macrophages had positive staining for CD14. An advantage of confocal microscopy was the ability to localize CD14 expression to the cell surface of AM in normal rabbits (Figure 1A). In contrast, tissue sections obtained from rabbits with E. coli pneumonia had variable amounts CD14 immunoreactivity, with many AM having little to no mCD14 (Figures 1C, 1E, and 1G). The presence of mCD14 on an AM next to an AM with no immunoreactivity for CD14 is important as it shows that the lack of positive staining is not due to failure of antigen preservation or the detection system (Figure 1C). On occasion, staining of the alveolar septa was observed in rabbits with E. coli pneumonia (Figure 1G). These findings suggest that mCD14 is downregulated on rabbit AM 24 h after exposure to E. coli in vivo.



View larger version (81K):
[in this window]
[in a new window]
  		Figure 1. Immunofluorescence for CD14 (red) and AM (green) in representative tissue sections obtained from rabbits treated with PBS (A) or live E. coli (C, E, and G). DIC was performed on the same regions to provide structural details (B, D, F, and H). White arrows designate AM where mCD14 is present, and yellow arrows identify macrophages where mCD14 is significantly decreased or absent. The insets are enlarged images of the AM designated by the larger arrows. (G) Positive staining for CD14 (red) on an alveolar septal wall (arrowhead). (H) DIC image of G showing location of alveolar macrophage (arrow) and the alveolar septa (arrowhead). Scale bar is 40 µm in A–F and 8 µm in G and H. CD14 was detected using goat anti-rabbit CD14 antibody and Alexa-568 (red), rabbit AM were detected with mouse anti-rabbit macrophage antibody and FITC (green), and nuclei were counterstained with To-Pro (blue).

 
Effects of LPS and E. coli on Expression of Membrane CD14 on AM
To confirm observations made with immunohistochemistry and to study the effects of LPS and E. coli on the expression of mCD14 on rabbit AM, experiments were performed in vitro. SDS-PAGE and Western blots as well as flow cytometry were used to measure CD14 expression in AM obtained from normal rabbits and stimulated in the presence of PBS, LPS (100 ng/ml), or E. coli (1 x 106 cfu/ml) for 24 h in vitro (Figure 2). After 24 h of incubation, more than 85% of the cells were alive by trypan blue exclusion method, and no differences in AM viability were observed between the treatment groups. CD14 expression was decreased in Western blot analysis of AM incubated with either LPS or E. coli (Figure 2A). There were detectable amounts of CD14 in cell lysates obtained from AM treated with E. coli when the Western blot was incubated with the film for longer periods of time. However, this resulted in saturation of the bands in lanes containing AM lysates from PBS- and LPS-treated macrophages (data not shown). Studies performed with flow cytometry show that incubation of normal AM with either LPS or E. coli significantly reduced the expression of CD14 on the cell surface (Figure 2B). Incubation with LPS reduced mCD14 by 30% (n = 9, P < 0.01), whereas incubation with live E. coli reduced mCD14 expression by 60% without affecting cell viability (n = 9, P < 0.01).



View larger version (20K):
[in this window]
[in a new window]
  		Figure 2. SDS-PAGE and Western blot of CD14 in AM lysates and flow cytometry of mCD14 expression on rabbit AM after incubation with PBS, LPS, or E. coli for 24 h. (A) Expression of CD14 was measured by SDS-PAGE and Western blotting using a goat anti-rabbit CD14 polyclonal antibody. Lane 1: AM treated with PBS; lane 2: AM treated with LPS; lane 3: AM treated with E. coli. (B) Flow cytometry showing the amount of mCD14 present on AM after incubation with PBS, LPS, or E. coli. #P = 0.001 as compared with 24 h PBS group. *P = 0.0007 compared with PBS group. MFI, mean fluorescence intensity. Values are mean ± SEM.

 
Components of E. coli Responsible for Downregulation of mCD14 on AM
To investigate the role of LPS in the downregulation of mCD14 induced by E. coli, we preincubated cells with polymyxin B (10 µg/ml) for 30 min, and then added either LPS or live E. coli and continued incubating the AM for 24 h. Preliminary studies showed that this concentration of polymyxin B had maximal inhibitory effects in AM incubated with E. coli for 24 h, but had no effect on the expression of mCD14 on AM incubated with PBS for 24 h. The MFI for mCD14 on AM pretreated with polymyxin B and then incubated with PBS for 24 h was 237.7 ± 37.7 versus the MFI for mCD14 on AM pretreated with PBS and then incubated with PBS for 24 h, which was 248.9 ± 43.1. Polymyxin B pretreatment completely blocked the ability of LPS to decrease the expression of mCD14 on AM (Figure 3). In contrast, polymyxin B pretreatment returned the cell surface expression of CD14 to 47% of the baseline when AM were incubated with E. coli. Taken together, polymyxin B totally abolished the LPS-induced downregulation of mCD14, but only partially reduced the effects of E. coli. To exclude the possibility that there were extremely high amounts of LPS in the supernatant of AM exposed to E. coli, which were not blocked by 10 µg/ml polymyxin B, we measured the concentration of LPS in the supernatants using the limulus amebocyte lysate assay method. The results showed that the concentrations of LPS in the supernatant of rabbit AM incubated with 4-h and 24-h E. coli were 14.18 ± 6.16 ng/ml and 15.02 ± 7.67 ng/ml, respectively. Thus, components of E. coli other than LPS appear to contribute to the effects of E. coli on rabbit AM.



View larger version (19K):
[in this window]
[in a new window]
  		Figure 3. Effect of polymyxin B on LPS- or E. coli–induced decrease in mCD14 expression. Cells were pretreated with PBS or polymyxin B (10 ng/ml) for 30 min before the addition of PBS, LPS (100 ng/ml), or E. coli (1 x 106 cfu/ml) for 24 h. The expression of mCD14 was measured by flow cytometry. (A) Representative histogram of mCD14 expression on rabbit AM pretreated with PBS or polymyxin B and then exposed to PBS or LPS for 24 h. 1) Thick solid line, isotype control; 2) dashed line, 24 h PBS + LPS; 3) dotted line, 24 h PBS + PBS (PBS control); 4) thin solid line, 24 h polymixin B + LPS. (B) Representative histogram of mCD14 expression on rabbit AM pretreated with PBS or polymyxin B and then exposed to PBS or E. coli for 24 h. 1) Thick solid line, isotype control; 2) dashed line, 24 h PBS + E. coli; 3) thin solid line, 24 h polymixin B + E. coli; 4) dotted line, 24 h PBS + PBS (PBS control). (C) Data from six separate experiments were normalized as a percentage of the mean fluorescent intensity (MFI) of the PBS control. The black bars are the data from AM pretreated with PBS and the gray bars are the data from AM pretreated with polymyxin B. Values are mean ± SEM. #P = 0.003 for polymyxin B + 24 h LPS group versus PBS + 24 h (n = 4). *P = 0.02 for polymyxin B + 24 h E. coli versus PBS + 24 h E. coli (n = 6).

 
Role of E. coli Products on the Expression of mCD14
Porphyromonas gingivalis produces cysteine proteinases that proteolytically cleave CD14 from cell surface of monocytes (20). To determine whether products actively secreted by live E. coli, such as phospholipases or proteases, play a role in the downregulation of mCD14 on AM, we compared the ability of live and heat-killed E. coli to decrease the cell surface expression of CD14. Surprisingly, there was no difference in the ability of live and heat-killed E. coli to decrease mCD14 on AM (54.01 ± 8.49 versus 59.74 ± 6.16% for live versus heat-killed bacterial respectively, as compared with the PBS controls at 24 h). These data suggest that E. coli decreased expression of mCD14 on AM by a mechanism other than actively secreted bacterial products.

Role of MAP Kinase in LPS- and E. coli–Induced Reduction of mCD14
LPS activation of macrophages increases tyrosine-phosphorylation of several MAP kinases including p38, ERK (Figure 4), and JNK (25–28). The role of MAP kinases in LPS- and E. coli–induced decrease in mCD14 expression was studied using specific pharmacologic inhibitors that blocked the p38, ERK, and JNK kinases. Blockade of the p38 (SB203580) or JNK (SP600125) pathways did not alter the affects of either LPS or live E. coli on mCD14 expression (Figure 4). In contrast, mCD14 expression was returned to 82 ± 6.9% of the baseline value when the ERK pathway was blocked in AM incubated with LPS. Blockade of the ERK pathway returned the expression of mCD14 back to 59 ± 6.6% of baseline in AM incubated with E. coli (Figure 4). Thus, blockade of ERK, but not p38 or JNK, attenuated the effects of LPS and E. coli on mCD14 expression, and blockade of the ERK pathway was more effective in LPS than in E. coli–treated AM.



View larger version (29K):
[in this window]
[in a new window]
  		Figure 4. Role of MAP-kinase pathways in the regulation of mCD14 expression on AM exposed to LPS or E. coli for 24 h in vitro. (A) Western blot analysis of phosphorylated- and total-ERK in cell lysates from AM treated with PBS (lane 1), LPS (lane 2), or E. coli (lane 3). (B) AM were preincubated with either DMSO, 10 µM SB203580 for blockade of p38 pathways, 25 µM SP600125 for blockade of JNK pathways, or 30 µM PD98059 for blockade of ERK pathways for 30 min before adding either LPS (100 ng/ml; black bars) or E. coli 1 x 106 cfu/ml (gray bars) for 24 h. The expression of mCD14 was measured by flow cytometry and the data are expressed as a percentage of the 24 h PBS control group. Values are mean ± SEM, #P = 0.03 for ERK pathway blockade in LPS-treated AM as compared with DMSO group (n = 4), and *P = 0.006 for ERK pathway blockade in E. coli–treated AM as compared with DMSO group (n = 6).

 
The Role of Proteases and Phosphatidylinositol-Specific Phospholipase
CD14 is anchored in the cell membrane by a glycosylphosphatidylinositol tail, and PI-PLC cleaves CD14 from the cell surface (11). However, Bazil and coworkers (29) found that protease-dependent shedding was the mechanism for phorbol myristate acetate (PMA)-induced downregulation of mCD14 on blood monocytes. To determine whether proteases or PI-PLC decrease the expression of mCD14, AM were treated with either 100 µM of ET-18-OCH3, a specific inhibitor of PI-PLC (30), or a protease inhibitor cocktail that blocks serine, cysteine, aspartic, and aminopeptidases for 30 min before incubation with LPS or E. coli. Inhibition of proteases blocked the LPS-induced decrease of mCD14 on AM, but did not alter the effects of E. coli on mCD14 expression (Figure 5). In contrast, inhibition of phospholipase did not prevent the downregulation of mCD14 by either LPS or E. coli (Figure 5). These data demonstrate that phospholipase activation is not responsible for either LPS- or E. coli–induced downregulation of mCD14, whereas a protease is responsible for LPS-induced but not E. coli–induced downregulation of mCD14. To further investigate the involvement of proteases in the shedding of mCD14, we measured the concentrations of sCD14 in the supernatants of the culture media from AM stimulated with LPS or E. coli with or without protease inhibitor pretreatment. LPS treatment significantly increased the amount of sCD14 in the supernatants at 24 h (Figure 6), and pretreatment with the protease inhibitor mixture abrogated the LPS effects. In preliminary studies, sCD14 was not directly affected by the protease inhibitor mixture. Thus, the decreased expression of mCD14 on AM stimulated by LPS occurs by protease-dependent cleavage of mCD14. In contrast, inhibition of proteases did not affect the amount of sCD14 in the supernatants of AM incubated with either E. coli or PBS. This suggests that a different mechanism is responsible for the decreased expression of mCD14 when AM are incubated with E. coli.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 5. Effects of phospholipase and protease inhibition on mCD14 expression on AM. Rabbit AM were preincubated for 30 min with ET-18-OCH3 (100 µM) or a protease inhibitor mixture and then incubated with LPS 100 ng/ml (black bars) or E. coli 1 x 106 cfu/ml (gray bars) for 24 h. The expression of mCD14 was measured by flow cytometry and the data are expressed as a percentage of the values of the 24 h PBS control group. Values are mean ± SEM. #P = 0.002 as compared with 24 h LPS +PBS group, n = 4.

 


View larger version (23K):
[in this window]
[in a new window]
  		Figure 6. Effects of LPS and E. coli on sCD14 in the AM supernatants. AM were incubated with 100 ng/ml LPS (black bars) or 1 x 106 cfu/ml E. coli (gray bars) for 24 h with or without prior treatment with the protease inhibitor mixture for 30 min. The concentration of sCD14 was determined by ELISA. Values are mean ± SEM. #P = 0.05 as compared with incubation without LPS or protease inhibitors; *P = 0.01 as compared with incubation with a combination of LPS and protease inhibitors, n = 4.

 
Effects of LPS and E. coli on the Response of AM to a Second Challenge with S. aureus or Zymosan
Human monocytes and macrophages exposed to LPS for 3–24 h are rendered tolerant to a second challenge with LPS (17). A potential mechanism whereby endotoxin tolerance develops is the downregulation of mCD14 on macrophages (16, 20). To compare the effects of LPS and E. coli on the subsequent responses of AM, we incubated AM with E. coli, S. aureus, or zymosan after pre-exposure to either LPS or live E. coli. Phagocytosis of E. coli, S. aureus, or zymosan was not altered following incubation with LPS or E. coli for 24 h (Figure 7A). In contrast, the production of TNF-{alpha} in response to E. coli was attenuated in AM after 24 h incubation with either LPS (34.6 ± 3.34 ng/ml) or E. coli (15.48 ± 3.71 ng/ml) as compared with PBS (45.63 ± 5.06 ng/ml) (Figure 7B). In addition, there was a positive correlation between the amount of mCD14 on the cell surface of AM and TNF-{alpha} production (Figure 8). The production of TNF-{alpha} after incubation with S. aureus was significantly reduced in AM pretreated with E. coli (22.78 ± 8.18 ng/ml) but not LPS (56.78 ± 6.39 ng/ml) as compared with PBS (56.15 ± 3.3 ng/ml) (Figure 7B). After incubation with E. coli for 24 h, AM were hyporesponsive to zymosan-induced production of TNF-{alpha} (9.44 ± 2.2 ng/ml versus 23.65 ± 3.49 ng/ml for PBS, P = 0.03, n = 4). Incubation of AM with LPS (23.35 ± 1.9 ng/ml) for 24 h did not affect the TNF-{alpha} response to zymosan. The production of TNF-{alpha} in response to a second challenge with S. aureus or zymosan did not show any relationship with the amount of CD14 on the cell surface. When the amount interleukin (IL)-8 was measured in the same biological samples, prior exposure of AM to either LPS or E. coli did not affect the production of IL-8 in response to a second challenge (data not shown).



View larger version (33K):
[in this window]
[in a new window]
  		Figure 7. Rabbit AM were incubated with PBS (black bars), LPS (100 ng/ml; light gray bars) or E. coli (1 x 106 cfu/ml; dark gray bars) for 24 h, and then the second stimulus of BODIPY-labeled E. coli, S. aureus, or zymosan was added to the AM at a ratio of 10:1. (A) Phagocytosis of E. coli, S. aureus, and zymosan was measured by flow cytometry after incubation of AM with BODIPY-labeled bioparticles for 2 h. Data are expressed as the percentage of AM that phagocytized fluorescent bioparticles. (B) The concentration of TNF-{alpha} in the supernatants of AM cultured with E. coli, S. aureus, or zymosan for 4 h was determined by ELISA. #P = 0.03, *P = 0.02, {psi}P = 0.009, {phi}P = 0.03 as compared with pretreatment with PBS, n = 4.

 


View larger version (12K):
[in this window]
[in a new window]
  		Figure 8. Positive correlation between the production of TNF-{alpha} and expression of mCD14 on AM exposed to E. coli as the second stimulus. Rabbit AM were pretreated with PBS, LPS, or E. coli for 24 h and then exposed to E. coli, and the amount of TNF-{alpha} produced in response to the second challenge with E. coli was determined. TNF-{alpha} was measured in AM supernatant using an ELISA for rabbit TNF-{alpha}, and the amount of mCD14 on AM was quantitated with flow cytometry using a goat anti-rabbit CD14 polyclonal antibody. Correlation between mCD14 and TNF-{alpha} was analyzed using Pearson's coefficient of correlation (r = 0.065; P = 0.02).

 
Taken together, phagocytosis and production of IL-8 were preserved in AM after 24 h incubation with either LPS or E. coli, whereas the production of TNF-{alpha} in response to a second challenge with E. coli was impaired after prior incubation with LPS and E. coli. In contrast, hyporesponsiveness of TNF-{alpha} production in response to S. aureus or zymosan was observed in AM pretreated with E. coli but not LPS.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The purpose of this study was to examine the regulation of mCD14 in bacterial pneumonia and to explore the mechanisms and consequences of changes in mCD14 expression. Studies performed with immunohistochemistry for rabbit CD14 in normal lungs and lungs from rabbits with E. coli pneumonia showed that prior exposure to E. coli decreased the positive staining for mCD14 on AM in vivo. Studies performed in vitro to determine the mechanisms responsible for modifying the expression of mCD14 on AM show that LPS decreased the expression of mCD14 by a protease-dependent mechanism. When compared with LPS, E. coli caused a more profound decrease in mCD14 expression on AM and the decreased expression of mCD14 caused by E. coli did not require proteases. In studies to evaluate the development of tolerance to a second stimulus, the prior incubation of AM with LPS and E. coli resulted in the development of tolerance to E. coli. In contrast, E. coli but not LPS resulted in the development of cross-tolerance to S. aureus and zymosan. The development of cross-tolerance to S. aureus and zymosan did not correlate with changes in the expression of mCD14 on AM suggesting that other mechanisms are responsible for the development of tolerance in macrophages. This suggests that prior exposure to whole E. coli may result in dysregulation of the innate immune response to diverse microbial pathogens in the lungs.

Incubation of AM with LPS and E. coli caused a significant decrease in mCD14 expression on AM (Figures 1 and 2). Previous studies show that LPS and E. coli alter the amounts of mCD14 on monocytes and macrophages, but the results are contradictory because of differences in cell types, endotoxin concentrations, and incubation times (31, 32). In the work of Fahmi and Chaby (33), there was a decrease of LPS-binding sites on macrophages treated with LPS, which is in agreement with our results. In contrast, Landmann and colleagues reported an increase in mCD14 on monocytes after incubation with LPS or E. coli (31). In their study LPS increased the expression of mCD14 on monocytes, whereas in our studies LPS reduced mCD14 expression on rabbit AM in vitro. Monocytes and macrophages, although derived from the same cellular lineage, are distinct in differentiation and maturation. The expression of cell surface markers and cytokine production in response to LPS (34), and the expression of CD14 on the surface of monocytes and macrophages differ (32).

To identify which components of E. coli were responsible for the decreased expression of mCD14, polymyxin B was used to block the effects of LPS and E. coli (Figure 3). Polymyxin B is a cationic, cyclic peptide antibiotic that inhibits the biological activities of LPS, including binding of LPS to leukocytes (5) and LPS-induced production of cytokines by macrophages (35). The results showed that LPS-induced downregulation of mCD14 expression was completely abolished by preincubation with polymyxin B, whereas the E. coli–induced reduction in expression of mCD14 was only partially attenuated by incubation with polymyxin B. To ensure that an excess of LPS in the supernatants of the whole bacteria did not exceed the neutralizing capacity of polymyxin B, the LPS in these supernatants was measured. The LPS in supernatants of whole E. coli was relatively low (15.02 ± 3.43 ng/ml), which is in agreement with other reports (5, 31). Because a large excess of polymyxin B was used relative to the measured concentration of LPS, it is likely that other bacterial components aside from LPS are responsible for the E. coli–induced downregulation of mCD14 expression on rabbit AM.

To determine whether secreted bacterial products were responsible for the decreased expression of mCD14 on rabbit AM, we compared the potency of live and heat-killed E. coli. There was no difference in the ability of live and heat-killed bacteria to decrease the expression of mCD14 on rabbit AM. Therefore, it is unlikely that the effect of live E. coli is due to secreted bacterial products as has been reported for Porphyromonas gingivalis, which produces cysteine proteinases that proteolytically cleave CD14 from cell surface of monocytes (20).

Numerous studies have demonstrated that mCD14, which belongs to the family of glycosylphosphatidylinositol-anchored glycoproteins, can be released from cells by treatment with PI-PLC (11, 36). However, it also has been reported that protease-dependent shedding causes downregulation of mCD14 on PMA-stimulated monocytes (29). To determine whether PI-PLC or proteases play a role in decreasing the expression of mCD14, we used specific inhibitors to block the effect of these enzymes. Inhibition of PI-PLC did not prevent the decreased expression of mCD14 caused by LPS or E. coli (Figure 5). In contrast, inhibition of proteases completely blocked the LPS-induced reduction of mCD14, whereas protease inhibitors had no effect on mCD14 expression of AM incubated with E. coli. To confirm this finding, we measured the concentrations of sCD14 in cell culture supernatants. The concentrations of sCD14 were increased by incubation of AM with LPS, but not with live E. coli. Furthermore, the LPS-induced shedding of sCD14 into the AM supernatants was abolished by pretreatment with the mixture of protease inhibitors (Figure 6). Therefore, the LPS-induced downregulation of mCD14 on rabbit AM appears to be mediated by protease-dependent cleavage of mCD14 from the cell surface and the proteases must derive from the AM after activation with LPS. In contrast, the E. coli–induced decrease of mCD14 on rabbit AM is mediated by mechanisms other than protease-dependent shedding.

A possible mechanism that could account for the decreased expression of mCD14 on AM exposed to E. coli without a reciprocal increase in sCD14, is the internalization of mCD14 during the process of phagocytosis (37, 38). Monocytes have been reported to internalize E. coli using a CD14-dependent pathway (7). In contrast, studies suggest that mCD14 and LPS molecules are internalized independently after association on the cell surface (39). To determine whether phagocytosis was the mechanism responsible for the decreased expression of mCD14, AM were incubated with Bodipy-labeled E. coli at 0, 5, 15, 30, 60, 120, and 240 min, and bacterial phagocytosis was measured with flow cytometry. This study showed that phagocytosis of E. coli by AM was maximal at 2 h. When mCD14 was measured at 4 h, there was no difference in the expression of mCD14 on AM that had been treated with PBS (215.2, ± 37.6, MFI), LPS (201.2 ± 47.3, and MFI), or that had maximal uptake of Bodipy-labeled E. coli (223.7 ± 39.2 MFI). This suggests that phagocytosis is not the mechanism responsible for the decreased expression of mCD14 on AM exposed to E. coli. The finding that CD14 expression in cell lysates is significantly decreased in Western blots of AM exposed to E. coli for 24 h is additional evidence that phagocytosis and internalization of cell surface CD14 is not the mechanism responsible for the decrease in mCD14 (Figure 2A). Future experiments are required to define the precise mechanism responsible for the E. coli–induced downregulation of mCD14 expression.

In monocytes and macrophages, MAP kinases are an important family of protein-serine/threonine kinases that mediate responses to LPS (13). MAP kinases regulate proliferation and differentiation (40) and in this report we show that the ERK pathway regulates the expression of mCD14 on the macrophage surface. Blockade of the ERK pathway attenuated 60% of LPS and 44% of E. coli–induced downregulation of mCD14. In contrast, blockade of the p38 and JNK pathways did not attenuate the effect of LPS or E. coli on mCD14 expression on rabbit AM. This suggests that the ERK pathway plays an important role in regulating the decreased expression of mCD14 when AM are exposed to either LPS or E. coli.

Human monocytes and macrophages exposed to endotoxin for 3–24 h are rendered tolerant and show a suppressed TNF-{alpha} response when rechallenged with LPS (17). A potential mechanism for the development of endotoxin tolerance is the decreased cell surface expression of CD14 (16, 20). The production of TNF-{alpha} in response to a second challenge with E. coli was attenuated after primary incubation with either LPS or E. coli. In contrast, the production of TNF-{alpha} in response to S. aureus or zymosan was impaired only in AM pretreated with E. coli but not LPS. Prior studies have shown that monocytes pretreated with LPS respond normally to a second challenge with S. aureus (41, 42) or zymosan (43), in agreement with our results. However, whole E. coli results in cross-desensitization and development of hyporesponsiveness to a second challenge with S. aureus and zymosan. The results show that the production of TNF-{alpha} in response to a secondary challenge with E. coli correlates well with the amount of CD14 on the cell surface of AM, but altered expression of mCD14 could not explain the different responses to secondary challenge with S. aureus or zymosan in LPS and E. coli–pretreated AM. The observation that the production of IL-8 was not decreased in the same supernatants in which TNF-{alpha} production was significantly decreased suggests differential desensitization of cytokine- and chemokine-signaling pathways, as reported for human monocytes and macrophages, and is further evidence that decreased mCD14 is not the mechanism responsible for endotoxin-tolerance (44).

TLR2 is required for signaling by gram-positive bacteria (45) and zymosan (46), suggesting that decreased cell surface expression of TLR2 could be the mechanism responsible for the cross-tolerance induced by E. coli. The expression of TLR2 on the cell surface of AM is unaffected by 24 h incubation with either LPS or E. coli (data not shown). Thus, decreased TLR2 expression on rabbit AM does not seem to be involved in the cross-tolerance response. Therefore, it seems likely that the tolerance develops downstream of mCD14 and TLR2, with alterations in signal transduction pathways being a possible explanation (17). The precise signaling pathways responsible for the different responses to LPS and E. coli will need to be clarified.

In conclusion, the expression of mCD14 is decreased on AM from lung sections of rabbits with E. coli pneumonia. Studies performed in vitro show that LPS and E. coli decrease the expression of mCD14 on AM by different mechanisms. LPS induces a protease-dependent shedding of mCD14 into the cell supernatant, whereas E. coli elicits mechanisms other than cleavage of the mCD14 from the surface. In addition, LPS and E. coli induce different responses to a second challenge, with cross-tolerance to gram-positive bacteria or zymosan being developed after exposure of AM to E. coli but not LPS. These studies show that distinct mechanisms regulate the expression of mCD14 and the induction of tolerance in rabbit AM exposed to LPS and E. coli, and suggest that AM function is impaired at sites of bacterial infection in the lungs.


   Acknowledgments
 
This study was supported in part by NIH grants GM37696 and HL30542.

Received in original form August 15, 2003

Received in final form March 29, 2004


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. El-Solh, A. A., A. T. Aquilina, R. S. Dhillon, F. Ramadan, P. Nowak, and J. Davies. 2002. Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia. Am. J. Respir. Crit. Care Med. 166:1038–1043.[Abstract/Free Full Text]
  2. Park, D. R., V. L. Sherbin, M. S. Goodman, A. D. Pacifico, G. D. Rubenfeld, N. L. Polissar, and R. K. Root. 2001. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J. Infect. Dis. 184:268–277.[CrossRef][Medline]
  3. Fox-Dewhurst, R., M. K. Alberts, O. Kajikawa, E. Caldwell, M. C. Johnson, S. J. Skerrett, R. B. Goodman, J. T. Ruzinski, V. A. Wong, E. Y. Chi, and T. R. Martin. 1997. Pulmonary and systemic inflammatory responses in rabbits with gram-negative pneumonia. Am. J. Respir. Crit. Care Med. 155:2030–2040.[Abstract]
  4. Matute-Bello, G., C. W. Frevert, O. Kajikawa, S. J. Skerrett, R. B. Goodman, D. R. Park, and T. R. Martin. 2001. Septic shock and acute lung injury in rabbits with peritonitis: failure of the neutrophil response to localized infection. Am. J. Respir. Crit. Care Med. 163:234–243.[Abstract/Free Full Text]
  5. Katz, S. S., K. Chen, S. Chen, M. E. Doerfler, P. Elsbach, and J. Weiss. 1996. Potent CD14-mediated signalling of human leukocytes by Escherichia coli can be mediated by interaction of whole bacteria and host cells without extensive prior release of endotoxin. Infect. Immun. 64:3592–3600.[Abstract]
  6. Ulevitch, R. J., and P. S. Tobias. 1995. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13:437–457.[CrossRef][Medline]
  7. Schiff, D. E., L. Kline, K. Soldau, J. D. Lee, J. Pugin, P. S. Tobias, and R. J. Ulevitch. 1997. Phagocytosis of gram-negative bacteria by a unique CD14-dependent mechanism. J. Leukoc. Biol. 62:786–794.[Abstract]
  8. Devitt, A., O. D. Moffatt, C. Raykundalia, J. D. Capra, D. L. Simmons, and C. D. Gregory. 1998. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392:505–509.[CrossRef][Medline]
  9. Beutler, B., K. Hoebe, X. Du, and R. J. Ulevitch. 2003. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J. Leukoc. Biol. 74:479–485.[Abstract/Free Full Text]
  10. Aderem, A., and R. J. Ulevitch. 2000. Toll-like receptors in the induction of the innate immune response. Nature 406:782–787.[CrossRef][Medline]
  11. Martin, T. R., S. M. Mongovin, P. S. Tobias, J. C. Mathison, A. M. Moriarty, D. J. Leturcq, and R. J. Ulevitch. 1994. The CD14 differentiation antigen mediates the development of endotoxin responsiveness during differentiation of mononuclear phagocytes. J. Leukoc. Biol. 56:1–9.[Abstract]
  12. Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, and M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189:1777–1782.[Abstract/Free Full Text]
  13. Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human monocytes. Cell. Signal. 13:85–94.[CrossRef][Medline]
  14. da silva Correia, J., K. Soldau, U. Christen, P. S. Tobias, and R. J. Ulevitch. 2001. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex: transfer from CD14 to TLR4 and MD-2. J. Biol. Chem. 276:21129–21135.[Abstract/Free Full Text]
  15. Frevert, C. W., G. Matute-Bello, S. J. Skerrett, R. B. Goodman, O. Kajikawa, C. Sittipunt, and T. R. Martin. 2000. Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J. Immunol. 164:5439–5445.[Abstract/Free Full Text]
  16. Dobrovolskaia, M. A., and S. N. Vogel. 2002. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect. 4:903–914.[CrossRef][Medline]
  17. West, M. A., and W. Heagy. 2002. Endotoxin tolerance: a review. Crit. Care Med 30:S64–S73.[CrossRef][Medline]
  18. Wolk, K., W. D. Docke, V. von Baehr, H. D. Volk, and R. Sabat. 2000. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 96:218–223.[Abstract/Free Full Text]
  19. Heagy, W., C. Hansen, K. Nieman, M. Cohen, C. Richardson, J. L. Rodriguez, and M. A. West. 2000. Impaired ex vivo lipopolysaccharide-stimulated whole blood tumor necrosis factor production may identify "septic" intensive care unit patients. Shock 14:271–276.[Medline]
  20. Sugawara, S., E. Nemoto, H. Tada, K. Miyake, T. Imamura, and H. Takada. 2000. Proteolysis of human monocyte CD14 by cysteine proteinases (gingipains) from Porphyromonas gingivalis leading to lipopolysaccharide hyporesponsiveness. J. Immunol. 165:411–418.[Abstract/Free Full Text]
  21. Kajikawa, O., R. B. Goodman, M. C. Johnson, K. Konishi, and T. R. Martin. 1996. Sensitive and specific immunoassays to detect rabbit IL-8 and MCP-1 cytokines that mediate leukocyte recruitment to the lungs. J. Immunol. Methods 197:19–29.[CrossRef][Medline]
  22. Kajikawa, O., M. C. Johnson, R. B. Goodman, C. W. Frevert, and T. R. Martin. 1997. A sensitive immunoassay to detect the alpha-chemokine GRO in rabbit blood and lung fluids. J. Immunol. Methods 205:135–143.[CrossRef][Medline]
  23. Loup, F., O. Weinmann, Y. Yonekawa, A. Aguzzi, H. G. Wieser, and J. M. Fritschy. 1998. A highly sensitive immunofluorescence procedure for analyzing the subcellular distribution of GABAA receptor subunits in the human brain. J. Histochem. Cytochem. 46:1129–1139.[Abstract/Free Full Text]
  24. van Gijlswijk, R. P., H. J. Zijlmans, J. Wiegant, M. N. Bobrow, T. J. Erickson, K. E. Adler, H. J. Tanke, and A. K. Raap. 1997. Fluorochrome-labeled tyramides: use in immunocytochemistry and fluorescence in situ hybridization. J. Histochem. Cytochem. 45:375–382.[Abstract/Free Full Text]
  25. Han, J., J. D. Lee, P. S. Tobias, and R. J. Ulevitch. 1993. Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J. Biol. Chem. 268:25009–25014.[Abstract/Free Full Text]
  26. Hambleton, J., S. L. Weinstein, L. Lem, and A. L. DeFranco. 1996. Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc. Natl. Acad. Sci. USA 93:2774–2778.[Abstract/Free Full Text]
  27. Ouadrhiri, Y., C. Pilette, R. C. Monteiro, J. P. Vaerman, and Y. Sibille. 2002. Effect of IgA on respiratory burst and cytokine release by human alveolar macrophages: role of ERK1/2 mitogen-activated protein kinases and NF-{kappa}B. Am. J. Respir. Cell Mol. Biol. 26:315–332.[Abstract/Free Full Text]
  28. Koch, A., M. Giembycz, K. Ito, S. Lim, E. Jazrawi, P. J. Barnes, I. Adcock, E. Erdmann, and K. F. Chung. 2004. Mitogen-activated protein kinase modulation of nuclear factor-{kappa}B–induced granulocyte macrophage–colony-stimulating factor release from human alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 30:342–349.[Abstract/Free Full Text]
  29. Bazil, V., and J. L. Strominger. 1991. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J. Immunol. 147:1567–1574.[Abstract]
  30. Powis, G., M. J. Seewald, C. Gratas, D. Melder, J. Riebow, and E. J. Modest. 1992. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res. 52:2835–2840.[Abstract/Free Full Text]
  31. Landmann, R., H. P. Knopf, S. Link, S. Sansano, R. Schumann, and W. Zimmerli. 1996. Human monocyte CD14 is upregulated by lipopolysaccharide. Infect. Immun. 64:1762–1769.[Abstract]
  32. Antal-Szalmas, P. 2000. Evaluation of CD14 in host defence. Eur. J. Clin. Invest. 30:167–179.[CrossRef][Medline]
  33. Fahmi, H., and R. Chaby. 1993. Desensitization of macrophages to endotoxin effects is not correlated with a down-regulation of lipopolysaccharide-binding sites. Cell. Immunol. 150:219–229.[CrossRef][Medline]
  34. Maus, U., S. Herold, H. Muth, R. Maus, L. Ermert, M. Ermert, N. Weissmann, S. Rosseau, W. Seeger, F. Grimminger, and J. Lohmeyer. 2001. Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:L58–L68.[Abstract/Free Full Text]
  35. Coyne, C. P., and B. W. Fenwick. 1993. Inhibition of lipopolysaccharide-induced macrophage tumor necrosis factor-alpha synthesis by polymyxin B sulfate. Am. J. Vet. Res. 54:305–314.[Medline]
  36. Haziot, A., S. Chen, E. Ferrero, M. G. Low, R. Silber, and S. M. Goyert. 1988. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J. Immunol. 141:547–552.[Abstract]
  37. Poussin, C., M. Foti, J. L. Carpentier, and J. Pugin. 1998. CD14-dependent endotoxin internalization via a macropinocytic pathway. J. Biol. Chem. 273:20285–20291.[Abstract/Free Full Text]
  38. Latz, E., A. Visintin, E. Lien, K. A. Fitzgerald, B. G. Monks, E. A. Kurt-Jones, D. T. Golenbock, and T. Espevik. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2–CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277:47834–47843.[Abstract/Free Full Text]
  39. Antal-Szalmas, P., M. J. Poppelier, R. Broekhuizen, J. Verhoef, J. A. van Strijp, and K. P. van Kessel. 2000. Diverging pathways for lipopolysaccharide and CD14 in human monocytes. Cytometry 41:279–288.[CrossRef][Medline]
  40. Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridges, and A. R. Saltiel. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92:7686–7689.[Abstract/Free Full Text]
  41. Mathison, J. C., G. D. Virca, E. Wolfson, P. S. Tobias, K. Glaser, and R. J. Ulevitch. 1990. Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages. J. Clin. Invest. 85:1108–1118.
  42. Roth, J., T. Aslan, B. Storr, and E. Zeisberger. 1997. Lack of cross tolerance between LPS and muramyl dipeptide in induction of circulating TNF-alpha and IL-6 in guinea pigs. Am. J. Physiol. 273:R1529–R1533.
  43. Zhang, X., and D. C. Morrison. 1993. Lipopolysaccharide-induced selective priming effects on tumor necrosis factor alpha and nitric oxide production in mouse peritoneal macrophages. J. Exp. Med. 177:511–516.[Abstract/Free Full Text]
  44. Kaufmann, A., D. Gemsa, and H. Sprenger. 2000. Differential desensitization of lipopolysaccharide-inducible chemokine gene expression in human monocytes and macrophages. Eur. J. Immunol. 30:1562–1567.[CrossRef][Medline]
  45. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, and C. J. Kirschning. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 274:17406–17409.[Abstract/Free Full Text]
  46. Underhill, D. M., A. Ozinsky, A. M. Hajjar, A. Stevens, C. B. Wilson, M. Bassetti, and A. Aderem. 1999. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401:811–815.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
J. T. Mao, D. P. Tashkin, I-H. Tsu, and K. J. Serio
Differential Modulation of Leukotriene B4 Synthesis and Degradation in Human Bronchoalveolar Lavage Cells by Lipopolysaccharide and Tobacco Smoke
Cancer Prevention Research, September 1, 2008; 1(4): 266 - 274.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. S. Berenson, C. T. Wrona, L. J. Grove, J. Maloney, M. A. Garlipp, P. K. Wallace, C. C. Stewart, and S. Sethi
Impaired Alveolar Macrophage Response to Haemophilus Antigens in Chronic Obstructive Lung Disease
Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 31 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
T. R. Martin and C. W. Frevert
Innate Immunity in the Lungs
Proceedings of the ATS, December 1, 2005; 2(5): 403 - 411.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. A. Daniel, T. H. Elsasser, A. Martinez, B. Steele, B. K. Whitlock, and J. L. Sartin
Interleukin-1{beta} and tumor necrosis factor-{alpha} mediation of endotoxin action on growth hormone
Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E650 - E657.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. P. Senft, T. R. Korfhagen, J. A. Whitsett, S. D. Shapiro, and A. M. LeVine
Surfactant Protein-D Regulates Soluble CD14 through Matrix Metalloproteinase-12
J. Immunol., April 15, 2005; 174(8): 4953 - 4959.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-0307OCv1
31/2/162    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, S.-M.
Right arrow Articles by Martin, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, S.-M.
Right arrow Articles by Martin, T. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2004 American Thoracic Society.